In vitro, the molecular silencing of DNMT1 decreased the expression of cell-cycle genes, such as CDK1, CCNA2, and E2F2, in GCB-DLBCL-derived cell lines.293 Analysis of DLBCL patients reported the overexpression of DNMT1, DNMT3A, and DNMT3B in 48%, 13%, and 45% of patients, respectively.294 Moreover, DNMT1 loss induced altered methylation levels and impaired tumor cell proliferation in mice with T-NHLs.295 Almost all T-NHL subtypes harbor mutations of DNMT3A. 296. The gene discussed is DNMT3A; the disease is neoplasm.